Skip to main content

Advertisement

SpringerLink
Log in

Benign prostatic hyperplasia burden comparison between China and United States based on the Global Burden of Disease Study 2019

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

To determine the difference in the burden of benign prostatic hyperplasia (BPH) between China and the United States from 1990 to 2019.

Methods

The prevalence, incidence, Years Lived with Disability (YLD), and their age-standardized rates for BPH in China and USA from 1990 to 2019 were based on the Global Burden of Disease Study 2019 (GBD 2019). The annual percentage changes (APC) of the age-standardized incidence rate (ASIR) and the age-standardized YLD rates (ASYR) were calculated using joinpoint regression analysis. The YLD numbers of six urinary tract diseases were also compared in both countries.

Results

The absolute burden of BPH increased continuously in both countries, but it was much higher in China than in the United States. The ASIR and ASYR of BPH decreased in China but remained stable or decreased slightly in the United States. BPH incidence and YLD rates decreased in all age groups in China from 1990 to 2019. In the USA, they varied by age group. BPH caused more YLD number than any other urinary tract disease in China. In the USA, prostate cancer (PCa) caused more YLDs than BPH.

Conclusions

This research reveals marked BPH burden differences between China and the US (1990–2019). China's higher burden necessitates targeted interventions, while unique trends in both countries demand tailored strategies. These insights enhance understanding of BPH dynamics, informing effective interventions across diverse contexts.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

Data will be made available on this website: (https://ghdx.healthdata.org/gbd-2019).

References

  1. Miernik A, Gratzke C (2020) Current treatment for benign prostatic hyperplasia. Dtsch Arzteblatt Int 117(49):843–854

    Google Scholar 

  2. Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK et al (2021) Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I—initial work-up and medical management. J Urol 206(4):806–817

    Article  PubMed  Google Scholar 

  3. Fusco F, Creta M, De Nunzio C, Iacovelli V, Mangiapia F, Li Marzi V et al (2018) Progressive bladder remodeling due to bladder outlet obstruction: a systematic review of morphological and molecular evidences in humans. BMC Urol 18(1):15

    Article  PubMed  PubMed Central  Google Scholar 

  4. Lee SWH, Chan EMC, Lai YK (2017) The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. Sci Rep 7(1):7984

    Article  PubMed  PubMed Central  Google Scholar 

  5. Lee AJ, Garraway WM, Simpson RJ, Fisher W, King D (1998) The natural history of untreated lower urinary tract symptoms in middle-aged and elderly men over a period of five years. Eur Urol 34(4):325–332

    Article  CAS  PubMed  Google Scholar 

  6. Platz EA, Smit E, Curhan GC, Nyberg LM, Giovannucci E (2002) Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in US men. Urology 59(6):877–883

    Article  PubMed  Google Scholar 

  7. Maserejian NN, Chen S, Chiu GR, Wager CG, Kupelian V, Araujo AB et al (2013) Incidence of lower urinary tract symptoms in a population-based study of men and women. Urology 82(3):560–564

    Article  PubMed  Google Scholar 

  8. Wang W, Guo Y, Zhang D, Tian Y, Zhang X (2015) The prevalence of benign prostatic hyperplasia in mainland China: evidence from epidemiological surveys. Sci Rep 26(5):13546

    Article  Google Scholar 

  9. Zhang S, Wang Q, Zhao D, Fu P, Qi K, Wang X et al (2023) Association of sensory impairment with Institutional Care Willingness among older adults in urban and rural China: an observational study. Innov Aging 7(3):igad013

    Article  PubMed  PubMed Central  Google Scholar 

  10. GBD 2019 Benign Prostatic Hyperplasia Collaborators (2022) The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Healthy Longev. 3(11):e754–e776

    Article  Google Scholar 

  11. GBD 2019 Diseases and Injuries Collaborators (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Lond Engl 396(10258):1204–1222

    Article  Google Scholar 

  12. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Lond Engl 392(10159):1789–1858

    Article  Google Scholar 

  13. Kim HJ, Fay MP, Feuer EJ, Midthune DN (2000) Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19(3):335–351

    Article  CAS  PubMed  Google Scholar 

  14. Clegg LX, Hankey BF, Tiwari R, Feuer EJ, Edwards BK (2009) Estimating average annual per cent change in trend analysis. Stat Med 28(29):3670–3682

    Article  PubMed  PubMed Central  Google Scholar 

  15. Lee HW, Kim SA, Nam JW, Kim MK, Choi BY, Moon HS (2014) The study about physical activity for subjects with prevention of benign prostate hyperplasia. Int Neurourol J 18(3):155–162

    Article  PubMed  PubMed Central  Google Scholar 

  16. Sun J, Li Y, Xiao LF, Shao NY, Liu M (2023) Flattening the curve after the initial outbreak of coronavirus disease 2019: a data-driven modeling analysis for the Omicron Pandemic in China. Vaccines 11(5):1009

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Li BH, Deng T, Huang Q, Zi H, Weng H, Zeng XT (2019) Body mass index and risk of prostate volume, international prostate symptom score, maximum urinary flow rate, and post-void residual in benign prostatic hyperplasia patients. Am J Mens Health 13(4):155798831987038

    Article  Google Scholar 

  18. Wu L, Li BH, Wang YY, Wang CY, Zi H, Weng H et al (2019) Periodontal disease and risk of benign prostate hyperplasia: a cross-sectional study. Mil Med Res 6(1):34

    PubMed  PubMed Central  Google Scholar 

  19. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB et al (2022) IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183:109119

    Article  PubMed  Google Scholar 

  20. Eke PI, Dye BA, Wei L, Slade GD, Thornton-Evans GO, Borgnakke WS et al (2015) Update on prevalence of periodontitis in adults in the United States: NHANES 2009 to 2012. J Periodontol 86(5):611–622

    Article  PubMed  PubMed Central  Google Scholar 

  21. Luo LS, Luan HH, Wu L, Shi YJ, Wang YB, Huang Q et al (2021) Secular trends in severe periodontitis incidence, prevalence and disability-adjusted life years in five Asian countries: a comparative study from 1990 to 2017. J Clin Periodontol 48(5):627–637

    Article  PubMed  Google Scholar 

  22. Yu EY, Siegal JA, Meyer GE, Ji XR, Ni XZ, Brawer MK (1997) Histologic differences in benign prostate hyperplasia between Chinese and American men. Prostate 31(3):175–179

    Article  CAS  PubMed  Google Scholar 

  23. Wei JT, Calhoun E, Jacobsen SJ (2005) Urologic diseases in America project: benign prostatic hyperplasia. J Urol 173(4):1256–1261

    Article  PubMed  Google Scholar 

  24. He H, Liang L, Han D, Xu F, Lyu J (2022) Different trends in the incidence and mortality rates of prostate cancer between China and the USA: a joinpoint and age-period-cohort analysis. Front Med 9:824464

    Article  Google Scholar 

  25. Vuichoud C, Loughlin KR (2015) Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol 22(Suppl 1):1–6

    PubMed  Google Scholar 

Download references

Funding

This study was supported by the National Natural Science Foundation of China (no. 82370779) and the Wisdom Accumulation and Talent Cultivation Project of the Third Xiangya Hospital of Central South University (no. 20210312).

Author information

Authors and Affiliations

  1. Department of Urology, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China

    Dingwen Liu, Cheng Li, Youyou Li, Liang Zhou, Jiaren Li, Yichuang Wang, Lei Zhou & Long Wang

  2. Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China

    Xiaomin Wan

Authors
  1. Dingwen Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cheng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Youyou Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Liang Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jiaren Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yichuang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiaomin Wan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lei Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Long Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

(I) Conception and design: LW, DL; (II) administrative support: YL, LZ; (III) provision of study materials or patients and collection and assembly of data: JL, YW, LZ; (IV) data analysis and interpretation: DL; (V) manuscript preparation: DL, CL; (VI) critical revision: LW, XW; (VII) final approval of manuscript: all authors.

Corresponding author

Correspondence to Long Wang.

Ethics declarations

Conflict of interest

The authors have disclosed that they have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article. The author declares that he has no conflict of interest.

Research involving human participants and/or animals

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

For this type of study formal consent is not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 2144 kb)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, D., Li, C., Li, Y. et al. Benign prostatic hyperplasia burden comparison between China and United States based on the Global Burden of Disease Study 2019. World J Urol 41, 3629–3634 (2023). https://doi.org/10.1007/s00345-023-04658-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-023-04658-8

Keywords

Search

Navigation